We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

28 hedge funds and large institutions have $69.9M invested in TScan Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more capital invested

Capital invested by funds: $20.3M → $69.9M (+$49.6M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

7.68% more ownership

Funds ownership: 51.04% → 58.72% (+7.7%)

0% more funds holding

Funds holding: 28 → 28 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.44%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
5
Increased
8
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LCM
Lynx1 Capital Management
Puerto Rico
+$14M
2
EC
EcoR1 Capital
California
+$13.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.25M
4
BI
BVF Inc
California
+$8.02M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.85M

Top Sellers

1
BlackRock
BlackRock
New York
-$675K
2
NM
Newtyn Management
New York
-$497K
3
BCM
Bridgeway Capital Management
Texas
-$174K
4
Morgan Stanley
Morgan Stanley
New York
-$61.3K
5
CC
Cannell Capital
Wyoming
-$30.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Lynx1 Capital Management
Puerto Rico
$13.1M +$14M +5,224,600 New
EC
2
EcoR1 Capital
California
$12.5M +$13.4M +5,000,000 New
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$10M +$9.25M +3,450,000 +627%
BI
4
BVF Inc
California
$7.47M +$8.02M +2,989,474 New
BBA
5
Baker Bros. Advisors
New York
$6.96M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.4M +$2.85M +1,062,464 +358%
BlackRock
7
BlackRock
New York
$3.16M -$675K -251,597 -17%
DMC
8
Deer Management Company
New York
$3.11M – – –
AI
9
Alphabet Inc
California
$2.69M – – –
SAM
10
Simplify Asset Management
Nevada
$2.62M +$1.34M +500,000 +91%
DF
11
DC Funds
Virginia
$1.57M – – –
MIM
12
Monashee Investment Management
Massachusetts
$1M +$1.07M +400,000 New
TCM
13
Tekla Capital Management
Massachusetts
$500K – – –
Renaissance Technologies
14
Renaissance Technologies
New York
$369K +$364K +135,862 +1,171%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$292K +$44.1K +16,449 +16%
Morgan Stanley
16
Morgan Stanley
New York
$271K -$61.3K -22,844 -17%
Stifel Financial
17
Stifel Financial
Missouri
$248K +$266K +99,000 New
NW
18
NewEdge Wealth
Pennsylvania
$229K – – –
BCM
19
Bridgeway Capital Management
Texas
$125K -$174K -65,000 -57%
State Street
20
State Street
Massachusetts
$96.3K +$38.9K +14,500 +60%
DIM
21
DC Investments Management
Virginia
$88.9K – – –
PFMU
22
Privium Fund Management (UK)
United Kingdom
$40K – – –
Northern Trust
23
Northern Trust
Illinois
$37.6K +$2.43K +905 +6%
WPW
24
Waldron Private Wealth
Pennsylvania
$25K – – –
UBS Group
25
UBS Group
Switzerland
$2.75K -$5.74K -2,140 -66%
1
2

TCRX Hedge Fund Activity: Q2 2023 in Review

28 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2023, worth a combined $69.9M — up 244% from $20.3M a quarter earlier.

Fund positioning in TCRX was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 4 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $14M. The largest seller was BlackRock, cutting an estimated $675K.

  • 28 institutional investors held TScan Therapeutics (TCRX) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $69.9M of TScan Therapeutics stock for Q2 2023, up 244% quarter-over-quarter.
  • 5 funds opened new TScan Therapeutics positions in Q2 2023 and 5 closed out, a net change of 0 holders.
  • The largest TScan Therapeutics buyer in Q2 2023 was Lynx1 Capital Management, an estimated $14M added.
  • The largest TScan Therapeutics seller in Q2 2023 was BlackRock, an estimated $675K sold.

Based on aggregated 13F filings for Q2 2023.